Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexibility of ultra-long-acting basal insulins around spontaneous exercise in type 1 diabetes
2019-003209-89Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin glargine and insulin degludec in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Medical University of Graz. Primary endpoint: Time in hypoglycaemia over 14-day exercise period. Started Sep 2019; status: completed.
02
Drugs
insulin glargineinsulin degludec
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2019-003209-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003209-89.